Sarepta Therapeutics (NASDAQ:SRPT) Earns “Buy” Rating from Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a note issued to investors on Tuesday,Benzinga reports. They currently have a $202.00 target price on the biotechnology company’s stock. Needham & Company LLC’s price target points to a potential upside of 70.56% from the stock’s previous close.

SRPT has been the subject of several other reports. Raymond James reiterated an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Royal Bank of Canada reissued an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Robert W. Baird cut their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Jefferies Financial Group started coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective on the stock. Finally, HC Wainwright restated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $118.43 on Tuesday. Sarepta Therapeutics has a 12 month low of $102.15 and a 12 month high of $173.25. The company has a market cap of $11.31 billion, a P/E ratio of 94.74 and a beta of 0.77. The business’s 50 day moving average is $122.04 and its two-hundred day moving average is $130.41. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SRPT. Daiwa Securities Group Inc. boosted its holdings in Sarepta Therapeutics by 28.7% during the second quarter. Daiwa Securities Group Inc. now owns 3,454 shares of the biotechnology company’s stock worth $546,000 after buying an additional 771 shares during the last quarter. American Century Companies Inc. boosted its stake in Sarepta Therapeutics by 14.1% during the 2nd quarter. American Century Companies Inc. now owns 7,184 shares of the biotechnology company’s stock worth $1,135,000 after acquiring an additional 889 shares during the last quarter. Oppenheimer Asset Management Inc. grew its holdings in Sarepta Therapeutics by 19.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 4,312 shares of the biotechnology company’s stock valued at $681,000 after purchasing an additional 708 shares during the period. Envestnet Asset Management Inc. increased its stake in Sarepta Therapeutics by 69.1% in the second quarter. Envestnet Asset Management Inc. now owns 68,679 shares of the biotechnology company’s stock valued at $10,851,000 after purchasing an additional 28,073 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in Sarepta Therapeutics in the second quarter worth $425,000. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.